This article was originally published in The Gray Sheet
Company plans to launch this year a cervical corpectomy cage intended to replace portions of the spine removed due to cancer. The company submitted a Humanitarian Device Exemption in late 1999 for the Class III device and anticipates FDA approval sometime in the first quarter, Chairman and CEO David Mercer reports at the recent U.S. Bancorp Piper Jaffray Health Care conference in New York City
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.